Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

INSPIRIS Kina PMCF-studie (INSPIRIS China)

29 september 2026 uppdaterad av: Edwards Lifesciences

Klinisk uppföljningsstudie efter marknaden av Edwards Lifesciences INSPIRIS RESILIA aortaklaff i kinesisk befolkning

The objective of this post-market trial is to evaluate long term safety and performance of the Edwards Lifesciences INSPIRIS RESILIA aortic valve in Chinese patients in a real-world clinical setting.

Studieöversikt

Status

Aktiv, inte rekryterande

Betingelser

Detaljerad beskrivning

The trial is a multi-center, prospective, single-arm study that will implant up to 250 subjects with the Edwards INSPIRIS RESILIA aortic valve and will continue to follow and assess them after implant for 5 years. In an effort to obtain sufficient long-term data, all subjects will be asked to reconsent to extended follow-up through 10 years.

Studietyp

Observationell

Inskrivning (Faktisk)

255

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100037
        • Fuwai Hospital, CAMS & PUMC
      • Beijing, Beijing Municipality, Kina, 100029
        • Beijing Anzhen Hospital, Capital Medical University
    • Fujian
      • Xiamen, Fujian, Kina, 361008
        • Xiamen Cardiovascular Hospital Xiamen University
    • Guangdong
      • Guangzhou, Guangdong, Kina, 510080
        • The First Affiliated Hospital, Sun Yat-sen University
      • Shenzhen, Guangdong, Kina, 518038
        • Fuwai Hospital Chinese Academy of Medical Sciences, Shenzhen
    • Henan
      • Zhengzhou, Henan, Kina, 450052
        • The First Affiliated Hospital of Zhengzhou University
      • Zhengzhou, Henan, Kina, 450008
        • Henan Provincial Chest Hospital
      • Zhengzhou, Henan, Kina, 451460
        • Fuwai Central China Cardiovascular Hospital
    • Jiangsu
      • Nanjing, Jiangsu, Kina, 210012
        • Nanjing First Hospital
    • Shaanxi
      • Xi'an, Shaanxi, Kina, 710065
        • The First Affiliated Hospital of Xi'an Jiaotong University
    • Sichuan
      • Chengdu, Sichuan, Kina, 610072
        • Sichuan Academy of Medical Sciences·Sichuan Provincial People's Hospital
    • Yunnan
      • Kunming, Yunnan, Kina, 650102
        • Fuwai Yunnan Cardiovascular Hospital

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Subjects requiring an elective replacement of their native or prosthetic aortic valve who have agreed to participate in the study.

Beskrivning

Inclusion Criteria:

  1. Subject is 18 years or older
  2. Subjects requiring an elective replacement of their native or prosthetic aortic valve as indicated per the IFU
  3. Subject is scheduled to undergo planned aortic valve replacement with or without concomitant coronary bypass surgery, with or without ascending aorta replacement
  4. Provide signed informed consent prior to the study participation

Exclusion Criteria:

  1. Valve implantation is contraindicated per the IFU
  2. Requires planned multiple valve replacement/ repair
  3. Has active endocarditis/myocarditis prior to the scheduled aortic replacement surgery
  4. Estimated Life expectancy< 12 months
  5. Current or recent participation (within 6 weeks prior to surgery) in another drug or device trial

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Observationsmodeller: COHORT
  • Tidsperspektiv: PROSPECTIVE

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
EDWARDS INSPIRIS RESILIA Aortic Valve

Subjects who were treated with the INSPIRIS RESILIA aortic heart valve.

Surgical replacement of the aortic valve with the INSPIRIS RESILIA Aortic Valve.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Subject's Occurrence Rate of Study Valve Related Death
Tidsram: 10 Years

The primary safety endpoint is the percentage of study valve related death which includes death caused by structural valve deterioration, nonstructural dysfunction, valve thrombosis, embolism, bleeding event, or operated valve endocarditis; death related to reintervention on the operated valve; or sudden, unexplained death.

10 Years
Subject's Occurrence Rate of Structural Valve Deterioration
Tidsram: 10 Years

The primary safety endpoint is the percentage of Structural Valve Deterioration which includes dysfunction or deterioration involving the operated valve (exclusive of infection or thrombosis), as determined by re-operation, autopsy, or clinical investigation.

10 Years
Subject's Occurrence Rate of Re-operation on the Study Valve
Tidsram: 10 Years

The primary safety endpoint is the reoperation rate on the study valve which is any operation that repairs, alters, or replaces the study valve, which occurs after the completion of the procedure and the transfer out of the procedure room.

10 Years
Subject's Occurrence Rate of Major Bleeding
Tidsram: 10 Years

The primary safety endpoint is the rate of major bleeding which is any episode of major internal or external bleeding that causes death, hospitalization, or permanent injury (e.g. Vision loss) or necessitates transfusion of 3 or more units of PRBC, pericardiocentesis, or exploration/reoperation for bleeding.

10 Years
Subject's Occurrence Rate of Thromboembolic Events
Tidsram: 10 Years

The primary safety endpoint is the rate of thromboembolic events which is an embolic event that occurs in absence of infection (endocarditis) starting from anesthesia time. Embolism may be manifested by a neurologic event (Stroke or Transient Ischemic Attack) or a non-cerebral embolic event.

10 Years
Subject's Occurrence Rate of Stroke
Tidsram: 10 Years

The primary safety endpoint is the rate of strokes which is a prolonged (>72 hours) or permanent neurologic deficit that is usually associated with abnormal results of magnetic resonance imaging or computed tomographic scans.

10 Years
Subject's Occurrence Rate of Transient Ischemic Attack
Tidsram: 10 Years

The primary safety endpoint is the rate of transient ischemic attacks which is characterized by fully reversible symptoms of short duration.

10 Years
Subject's Occurrence Rate of Non-Cerebral Thromboembolism
Tidsram: 10 Years

The primary safety endpoint is the rate of non-cerebral thromboembolism which is an embolus documented operatively, at autopsy, or clinically that produces signs or symptoms attributable to complete or partial obstruction of a peripheral artery (does not include deep vein thrombosis).

10 Years

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Subject's Average Mean Gradient at 10 Years
Tidsram: 10 Years

Hemodynamic performance - Mean gradients as evaluated by echocardiography

10 Years
Subject's Average Peak Gradient at 10 Years
Tidsram: 10 Years

Hemodynamic performance - Peak gradients as evaluated by echocardiography

10 Years
Subject's Average Effective Orifice Area at 10 Years
Tidsram: 10 Years

Hemodynamic performance - Effective Orifice Area evaluated by echocardiography

10 Years
Subject's Average Effective Orifice Area Index at 10 Years
Tidsram: 10 Years

Hemodynamic performance - Effective Orifice Area Index evaluated by echocardiography

10 Years
Amount of Aortic Central Regurgitation in Subjects at 10 Years
Tidsram: 10 Years

Hemodynamic performance - Aortic central regurgitation evaluated by echocardiography

10 Years
Amount of Aortic Paravalvular Regurgitation in Subjects at 10 Years
Tidsram: 10 Years

Hemodynamic performance - Aortic paravalvular regurgitation evaluated by echocardiography

10 Years

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Hansong Sun, Professor, Chinese Academy of Medical Sciences, Fuwai Hospital

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

13 juli 2022

Primärt slutförande (Beräknad)

1 mars 2034

Avslutad studie (Beräknad)

1 december 2034

Studieregistreringsdatum

Först inskickad

31 maj 2022

Först inskickad som uppfyllde QC-kriterierna

31 maj 2022

Första postat (Faktisk)

3 juni 2022

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

2 oktober 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

29 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • 2021-09

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

IPD-planbeskrivning

Individual participant data will not be available to other researchers.

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Ja

produkt tillverkad i och exporterad från U.S.A.

Ja

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera